This week's biggest news for IPF patients is that an AI system identified a seven-drug combination that, in computer simulations, kept lung function at 98.3% — nearly healthy levels.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
Researchers are working hard on IPF (a lung disease where scar tissue slowly replaces healthy lung). This week the database grew to nearly 4,800 studies and 1,400 clinical trials (real tests of treatments in people). Most new papers came from Russia and preprint servers — meaning fresh, early-stage findings shared before full review. Nothing in the recent papers directly targeted IPF, but the broad research activity shows the field is very busy.
The AI tested thousands of drug combinations and found one standout mix of seven drugs. Together they kept FVC (a measure of how much air your lungs can hold) at 98.3% in the simulation — that is almost the same as a healthy person's lungs. Each drug targets a different scar-forming pathway, so they work together like a team. These are still computer results, not yet tested in people, but they point researchers toward exciting real-world trials.
One question to ask your lung doctor at your next visit: 'Are any combination drug trials open right now that I might qualify for, especially ones targeting scarring from more than one angle at the same time?'